Our goal is to compare prognosis-related outcomes—overall survival (OS) and invasive disease-free survival (IDFS)—between BC patients with BRCA1 and BRCA2 and a matched control group without germline PV (BRCA-wt). This evidence concerns the gene BRCA2 and breast cancer.